Cargando…

Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia

BACKGROUND: Cognitive flexibility deficits are present in patients with schizophrenia and are strong predictors of functional outcome but, as yet, have no pharmacological treatments. AIMS: The purpose of this study was to investigate whether the phosphodiesterase type-4 inhibitor, roflumilast, can i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Livingston, Nicholas R, Hawkins, Peter CT, Gilleen, James, Ye, Rong, Valdearenas, Lorena, Shergill, Sukhi S, Mehta, Mitul A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435828/ https://www.ncbi.nlm.nih.gov/pubmed/33908296 http://dx.doi.org/10.1177/02698811211000778

Ejemplares similares

An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients
por: Gilleen, James, et al.
Publicado: (2018)

Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation‐induced deficits in spatial pattern separation
por: Heckman, Pim R. A., et al.
Publicado: (2020)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Impact of the COVID-19 pandemic on the mental health and well-being of UK healthcare workers
por: Gilleen, James, et al.
Publicado: (2021)

Dysregulated but not decreased salience network activity in schizophrenia
por: White, Thomas P., et al.
Publicado: (2013)

Corrigendum: Dysregulated but not decreased salience network activity in schizophrenia
por: White, Thomas P., et al.
Publicado: (2019)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Characterization of Resveratrol, Oxyresveratrol, Piceatannol and Roflumilast as Modulators of Phosphodiesterase Activity. Study of Yeast Lifespan
por: Matencio, Adrián, et al.
Publicado: (2020)

Effect of Roflumilast in airways disorders via dual inhibition of phosphodiesterase and Ca(2+)-channel
por: Imam, Faisal, et al.
Publicado: (2020)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Roflumilast, a type of phosphodiesterase 4 inhibitor, can reduce intestinal injury caused by sepsis
por: Zhang, Zhongyuan, et al.
Publicado: (2021)

The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice
por: Rieder, Florian, et al.
Publicado: (2013)

Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis-induced Acute Kidney Injury
por: Xu, Xingkai, et al.
Publicado: (2020)

T125. INCIDENCE OF TREATMENT RESISTANCE SCHIZOPHRENIA IN A COMMUNITY SAMPLE USING THE TRRIP CONCENSUS
por: Joyce, Dan, et al.
Publicado: (2018)

Exploring psychotic symptoms: a comparison of motor related neuronal activation during and after acute psychosis
por: Sheridan Rains, Luke, et al.
Publicado: (2012)

Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report
por: Patel, Sachin S, et al.
Publicado: (2010)

Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: A review of the literature
por: Patel, Sachin S, et al.
Publicado: (2010)

The Phosphodiesterase 4 Inhibitor Roflumilast Protects against Cigarette Smoke Extract-Induced Mitophagy-Dependent Cell Death in Epithelial Cells
por: Kyung, Sun Young, et al.
Publicado: (2018)

Facial affect processing deficits in schizophrenia: A meta-analysis of antipsychotic treatment effects
por: Gabay, Anthony S, et al.
Publicado: (2015)

A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia
por: di Hou, Meng, et al.
Publicado: (2021)

S148. DIFFERENTIAL NEURAL REWARD MECHANISMS IN TREATMENT RESPONSIVE AND TREATMENT RESISTANT SCHIZOPHRENIA
por: Vanes, Lucy, et al.
Publicado: (2018)

Roflumilast Ameliorates Isoflurane-Induced Inflammation in Astrocytes via the CREB/BDNF Signaling Pathway
por: Zhang, Chunyuan, et al.
Publicado: (2021)

White matter changes in treatment refractory schizophrenia: Does cognitive control and myelination matter?
por: Vanes, Lucy D., et al.
Publicado: (2018)

Retraction of “Roflumilast Ameliorates Isoflurane-Induced Inflammation in Astrocytes via the CREB/BDNF Signaling Pathway”
por: Zhang, Chunyuan, et al.
Publicado: (2021)

Phosphodiesterase-4 Inhibitor Roflumilast-Mediated Protective Effect in Sepsis-Induced Late-Phase Event of Acute Kidney Injury: A Narrative Review
por: Kazmi, Imran, et al.
Publicado: (2022)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report
por: Sanchez, Asiel Yair Adan, et al.
Publicado: (2016)

A Novel Virtual Reality Assessment of Functional Cognition: Validation Study
por: Porffy, Lilla Alexandra, et al.
Publicado: (2022)

F155. THE NEUROPHYSIOLOGICAL AND BEHAVIOURAL EFFECTS OF TRANSCRANIAL DIRECT CURRENT STIMULATION ON WORKING MEMORY AND EXECUTIVE FUNCTIONING IN SCHIZOPHRENIA
por: Orlov, Natasza, et al.
Publicado: (2018)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report — ADDENDUM
por: Sanchez, Asiel Yair Adan, et al.
Publicado: (2019)

The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice
por: Wang, Hao, et al.
Publicado: (2020)

Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
por: Luo, Jian, et al.
Publicado: (2016)

Neuroimaging oxytocin modulation of social reward learning in schizophrenia
por: Mouchlianitis, Elias D., et al.
Publicado: (2022)

F77. OXYTOCIN ENHANCES VISUAL ATTENTION TO FACIAL STIMULI IN PATIENTS WITH SCHIZOPHRENIA: EVIDENCE FROM AN EYE-TRACKING STUDY
por: Porffy, Lilla, et al.
Publicado: (2018)

Alpha3/alpha2 power ratios relate to performance on a virtual reality shopping task in ageing adults
por: Patchitt, Joel, et al.
Publicado: (2022)

O6.8. GLUTAMATERGIC DYSFUCTION AND TREATMENT RESPONSE IN MINIMALLY TREATED AND CHRONIC SCHIZOPHRENIA PATIENTS
por: Mouchlianitis, Elias, et al.
Publicado: (2018)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pasvft33q4ciifsaq783teb7os